|
EP2290071B1
(en)
|
2004-05-28 |
2014-12-31 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
|
EP2314688B1
(en)
*
|
2004-11-12 |
2014-07-16 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
|
WO2006107826A2
(en)
|
2005-04-04 |
2006-10-12 |
The Board Of Regents Of The University Of Texas System |
Micro-rna's that regulate muscle cells
|
|
AU2007299828C1
(en)
*
|
2006-09-19 |
2014-07-17 |
Interpace Diagnostics, Llc |
MicroRNAs differentially expressed in pancreatic diseases and uses thereof
|
|
JP5592251B2
(ja)
*
|
2007-04-30 |
2014-09-17 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション |
膵臓癌を正常な膵臓機能および/または慢性膵炎と識別する方法
|
|
WO2009036332A1
(en)
|
2007-09-14 |
2009-03-19 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
|
CA2705325C
(en)
*
|
2007-11-09 |
2016-11-01 |
The Board Of Regents Of The University Of Texas System |
Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
|
|
WO2009070805A2
(en)
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
|
CA2718520C
(en)
|
2008-03-17 |
2020-01-07 |
The Board Of Regents Of The University Of Texas System |
Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
|
|
EP2285960B1
(en)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
|
|
US7888035B2
(en)
|
2008-10-30 |
2011-02-15 |
Caris Mpi, Inc. |
Methods for assessing RNA patterns
|
|
WO2010054386A2
(en)
*
|
2008-11-10 |
2010-05-14 |
Battelle Memorial Institute |
Methods, compositions, and devices utilizing microrna to determine physiological conditions
|
|
EP3181705A1
(en)
|
2008-11-12 |
2017-06-21 |
Caris Life Sciences Switzerland Holdings GmbH |
Methods and systems of using exosomes for determining phenotypes
|
|
WO2010055487A2
(en)
*
|
2008-11-13 |
2010-05-20 |
Koninklijke Philips Electronics N.V. |
Compositions and methods for micro-rna expession profiling of colorectal cancer
|
|
CN103237901B
(zh)
|
2010-03-01 |
2016-08-03 |
卡里斯生命科学瑞士控股有限责任公司 |
用于治疗诊断的生物标志物
|
|
CA2795776A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers for disease
|
|
WO2011150855A1
(en)
*
|
2010-06-04 |
2011-12-08 |
Fudan University |
Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma
|
|
WO2012005572A1
(en)
|
2010-07-06 |
2012-01-12 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
JP2013542192A
(ja)
*
|
2010-09-27 |
2013-11-21 |
サバンチ ユニバーシテシ |
マクロオートファジーの異常を伴う疾患の診断、予防、治療及びフォローアップのための、miRNAの使用
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
|
US9850541B2
(en)
|
2011-12-19 |
2017-12-26 |
Valley Health System |
Methods and kits for detecting subjects at risk of having cancer
|
|
WO2013101783A2
(en)
|
2011-12-30 |
2013-07-04 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
|
WO2013170146A1
(en)
|
2012-05-10 |
2013-11-14 |
Uab Research Foundation |
Methods and compositions for modulating mir-204 activity
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
US20150344961A1
(en)
*
|
2012-09-11 |
2015-12-03 |
New York University |
Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
PT3363902T
(pt)
*
|
2012-12-06 |
2019-12-19 |
Sigma Aldrich Co Llc |
Modificação e regulação de genoma baseadas em crispr
|
|
HK1217215A1
(zh)
|
2013-01-17 |
2016-12-30 |
Modernatx, Inc. |
用於改变细胞表型的信号传感器多核苷酸
|
|
KR101501562B1
(ko)
*
|
2013-04-05 |
2015-03-11 |
연세대학교 산학협력단 |
췌장암 진단 마커를 검출하는 방법
|
|
US20150018230A1
(en)
*
|
2013-06-11 |
2015-01-15 |
Indiana University Research And Technology Corp. |
PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
|
|
JP6611411B2
(ja)
*
|
2013-12-05 |
2019-11-27 |
東レ株式会社 |
膵臓がんの検出キット及び検出方法
|
|
CA2939343A1
(en)
|
2014-02-18 |
2015-08-27 |
Baylor Research Institute |
Mir-320e and colorectal cancer
|
|
US9909190B2
(en)
|
2014-03-04 |
2018-03-06 |
Hiroshima University |
Method for assisting detection of pancreatic cancer
|
|
KR102747981B1
(ko)
|
2014-05-30 |
2024-12-31 |
국립연구개발법인 고쿠리츠간켄큐센터 |
췌장암의 검출 키트 또는 디바이스 및 검출 방법
|
|
US9623040B2
(en)
|
2014-07-14 |
2017-04-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Immunomodulation by controlling expression levels of microRNAs in dendritic cells
|
|
EP3041948B1
(en)
|
2014-11-10 |
2019-01-09 |
Modernatx, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
|
JP2016123340A
(ja)
*
|
2014-12-26 |
2016-07-11 |
株式会社エバンス |
膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤
|
|
WO2017127750A1
(en)
|
2016-01-22 |
2017-07-27 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
KR102781810B1
(ko)
|
2016-03-31 |
2025-03-18 |
국립연구개발법인 고쿠리츠간켄큐센터 |
조기 췌장암 또는 췌장암 전구 병변의 검출 키트 또는 디바이스 및 검출 방법
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
KR102469450B1
(ko)
|
2016-05-18 |
2022-11-22 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
AU2017286606A1
(en)
|
2016-06-14 |
2018-12-13 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN109661228A
(zh)
*
|
2016-06-20 |
2019-04-19 |
库拉肿瘤学公司 |
用erk抑制剂治疗鳞状细胞癌
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
EP4484443A3
(en)
|
2016-06-29 |
2025-03-26 |
CRISPR Therapeutics AG |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
|
CA3029132A1
(en)
|
2016-07-06 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of pain related disorders
|
|
JP7548696B2
(ja)
|
2016-07-06 |
2024-09-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
|
RU2765874C2
(ru)
|
2016-10-26 |
2022-02-04 |
МОДЕРНАТиЭкс, ИНК. |
Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
|
|
US11584932B2
(en)
|
2016-11-01 |
2023-02-21 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3576780A1
(en)
|
2017-02-01 |
2019-12-11 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
US11559588B2
(en)
|
2017-02-22 |
2023-01-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
|
|
US11920148B2
(en)
|
2017-02-22 |
2024-03-05 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
EP3585807A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
US20200216857A1
(en)
|
2017-02-22 |
2020-07-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US10636512B2
(en)
|
2017-07-14 |
2020-04-28 |
Cofactor Genomics, Inc. |
Immuno-oncology applications using next generation sequencing
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
US20190153440A1
(en)
|
2017-11-21 |
2019-05-23 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
WO2019117269A1
(ja)
|
2017-12-13 |
2019-06-20 |
国立大学法人広島大学 |
膵がんの検出を補助する方法
|
|
CA3084632A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a
|
|
WO2019152557A1
(en)
|
2018-01-30 |
2019-08-08 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
|
WO2019200171A1
(en)
|
2018-04-11 |
2019-10-17 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
BR112021014845A2
(pt)
|
2019-01-31 |
2021-11-03 |
Modernatx Inc |
Métodos de preparação de nanopartículas lipídicas
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
JP7418024B2
(ja)
*
|
2019-04-26 |
2024-01-19 |
国立大学法人大阪大学 |
トンネル電流を使用したマイクロrna解析
|
|
MA56539A
(fr)
|
2019-06-24 |
2022-04-27 |
Modernatx Inc |
Arn messager résistant à l'endonucléase et utilisations correspondantes
|
|
US20220387628A1
(en)
|
2019-06-24 |
2022-12-08 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
JP2023513043A
(ja)
|
2020-01-31 |
2023-03-30 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子を調製する方法
|
|
US11965162B2
(en)
*
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|
|
WO2022014670A1
(ja)
*
|
2020-07-16 |
2022-01-20 |
学校法人 久留米大学 |
膵臓がんのバイオマーカーとしてのマイクロrnaの使用
|
|
CN116710079A
(zh)
|
2020-07-24 |
2023-09-05 |
斯特兰德生物科技公司 |
包含经修饰的核苷酸的脂质纳米颗粒
|
|
KR20230167008A
(ko)
|
2020-08-06 |
2023-12-07 |
모더나티엑스, 인크. |
지질 나노입자의 제조 방법
|
|
US20240166707A1
(en)
|
2021-01-08 |
2024-05-23 |
Strand Therapeutics Inc. |
Expression constructs and uses thereof
|
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
|
AU2023227443A1
(en)
|
2022-03-01 |
2024-10-10 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
JP2025516226A
(ja)
|
2022-04-26 |
2025-05-27 |
ストランド セラピューティクス インコーポレイテッド |
ベネズエラウマ脳炎(vee)レプリコンを含む脂質ナノ粒子及びその使用
|
|
EP4561546A1
(en)
|
2022-07-29 |
2025-06-04 |
ModernaTX, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
|
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
|
EP4561547A1
(en)
|
2022-07-29 |
2025-06-04 |
ModernaTX, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
|
CN121079317A
(zh)
|
2023-04-28 |
2025-12-05 |
深圳深信生物科技有限公司 |
经修饰的递送载体及其应用
|
|
WO2024259373A1
(en)
|
2023-06-14 |
2024-12-19 |
Modernatx, Inc. |
Compounds and compositions for delivery of therapeutic agents
|
|
WO2025160381A1
(en)
|
2024-01-26 |
2025-07-31 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
WO2025166202A1
(en)
|
2024-01-31 |
2025-08-07 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
|
|
CN119391860B
(zh)
*
|
2024-12-25 |
2025-03-21 |
慧算基因科技(上海)有限公司 |
一种用于胰腺癌术后mrd检测及动态监测的引物探针组合物、试剂盒及应用
|